Asia to Dominate Growth in Pharma Contract Manufacturing

PRLog (Press Release) – Jul 21, 2010 – The global pharmaceutical industry has experienced numerous changes in terms of market trends over the recent few years. With the mounting cost pressure on the pharmaceutical companies due to the healthcare cost cutting measures in various countries, the trend of drugs contract manufacturing at low cost has become very important. As per a new research report, “Global Contract Manufacturing Market Analysis”, the global contract manufacturing market is expected to grow at a CAGR of around 12% during 2010-2012.

Research by RNCOS has found that currently North America is dominating the overall contract manufacturing market. However, the Asian countries have made most of the progress in terms of production capacity and facilities up gradation in recent years. The low cost manufacturing services are the major advantage that these CMOs in Asia have gained over other regions. In this regard, the report provides complete information and analysis of various pharmaceutical contract manufacturing destinations in Asia such as India, China, Vietnam, Bangladesh and South Korea.

RNCOS has studied various country level contract manufacturing markets based on their export volume of drugs and pharmaceuticals and production capacities. Besides, the report includes key contract manufacturers in these countries along with their business details. This will help the client in getting a clear overview of the overall market. Moreover, some other emerging market trends like Biomanufacturing and GMP regulation issues have also been studied in the report.

“Global Contract Manufacturing Market Analysis” is an outcome of extensive research and thorough analysis of the fast-growing pharmaceutical contract manufacturing industry worldwide. The report discusses market structure, current and past market performance and factors critical to the success of the industry. Moreover, the report gives industry forecast based on correlation of past drivers, challenges and opportunities for expansion. We have also identified all the key players in the Competitor Analysis section of the report. The section talks about the business profile and strategic moves of leading players operating in the sector. This report will help those clients planning to invest in the contract manufacturing industry or looking to outsource manufacturing of their products.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM265.htm

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization of two cancer drugs.

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.